Cancer Research UK
- Country
- π¬π§United Kingdom
- Ownership
- Private
- Established
- 2002-01-01
- Employees
- 1K
- Market Cap
- -
Technetium Tc 99m Demobesin-4 for Imaging Procedures in Patients With Prostate Cancer
- Conditions
- Prostate Cancer
- First Posted Date
- 2009-10-02
- Last Posted Date
- 2012-02-28
- Lead Sponsor
- Cancer Research UK
- Target Recruit Count
- 8
- Registration Number
- NCT00989105
- Locations
- π¬π§
Saint Bartholomew's Hospital, London, England, United Kingdom
AT9283 in Children and Adolescents With Relapsed and Refractory Solid Tumors
- Conditions
- Unspecified Childhood Solid Tumor, Protocol Specific
- First Posted Date
- 2009-09-29
- Last Posted Date
- 2019-11-29
- Lead Sponsor
- Cancer Research UK
- Target Recruit Count
- 33
- Registration Number
- NCT00985868
- Locations
- π¬π§
Birmingham Children's Hospital, Birmingham, England, United Kingdom
π¬π§Leeds General Infirmary, Leeds, England, United Kingdom
π¬π§Royal Manchester Children's Hospital, Manchester, England, United Kingdom
Combination Chemotherapy and Rituximab in Treating Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma
- Conditions
- Lymphoma
- First Posted Date
- 2009-09-10
- Last Posted Date
- 2013-08-26
- Lead Sponsor
- Cancer Research UK
- Target Recruit Count
- 150
- Registration Number
- NCT00974792
- Locations
- π¬π§
Nottingham City Hospital, Nottingham, England, United Kingdom
Study of Blood and Tissue Samples From Patients Receiving Androgen Deprivation for Newly Diagnosed Prostate Cancer
- Conditions
- Prostate Cancer
- First Posted Date
- 2009-08-28
- Last Posted Date
- 2014-01-10
- Lead Sponsor
- Cancer Research UK
- Target Recruit Count
- 120
- Registration Number
- NCT00967954
- Locations
- π¬π§
Cancer Research UK at Cambridge Research Institute, Cambridge, England, United Kingdom
Study of Tissue, Blood, and Urine Samples From Patients With Advanced Prostate Cancer
- Conditions
- Prostate Cancer
- First Posted Date
- 2009-08-28
- Last Posted Date
- 2013-08-12
- Lead Sponsor
- Cancer Research UK
- Registration Number
- NCT00967889
- Locations
- π¬π§
Cancer Research UK at Cambridge Research Institute, Cambridge, England, United Kingdom
Study of Blood and Tissue Samples From Patients With Stomach Cancer, Esophageal Cancer, or Gastroesophageal Junction Cancer
- Conditions
- Adenocarcinoma of the Gastroesophageal JunctionEsophageal CancerGastric Cancer
- First Posted Date
- 2009-08-21
- Last Posted Date
- 2013-08-12
- Lead Sponsor
- Cancer Research UK
- Target Recruit Count
- 4000
- Registration Number
- NCT00963092
- Locations
- π¬π§
Cancer Research UK at Cambridge Research Institute, Cambridge, England, United Kingdom
Donor Umbilical Cord Blood Transplant After Cyclophosphamide, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematologic Disease
- Conditions
- Hematopoietic/Lymphoid Cancer
- First Posted Date
- 2009-08-14
- Last Posted Date
- 2013-08-26
- Lead Sponsor
- Cancer Research UK
- Target Recruit Count
- 60
- Registration Number
- NCT00959231
- Locations
- π¬π§
Bristol Royal Hospital for Children, Bristol, England, United Kingdom
π¬π§Cancer Research UK Clinical Centre at St. James's University Hospital, Leeds, England, United Kingdom
π¬π§University College of London Hospitals, London, England, United Kingdom
Fludarabine, Cyclophosphamide, and Thalidomide in Treating Patients With Angioimmunoblastic T-Cell Lymphoma
- Conditions
- Lymphoma
- First Posted Date
- 2009-08-13
- Last Posted Date
- 2013-08-26
- Lead Sponsor
- Cancer Research UK
- Target Recruit Count
- 37
- Registration Number
- NCT00958854
- Locations
- π¬π§
Cancer Research UK and University College London Cancer Trials Centre, Exeter, England, United Kingdom
Carmustine, Etoposide, Cytarabine, Melphalan, and Alemtuzumab Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
- Conditions
- Lymphoma
- First Posted Date
- 2009-05-25
- Last Posted Date
- 2013-08-02
- Lead Sponsor
- Cancer Research UK
- Target Recruit Count
- 47
- Registration Number
- NCT00908180
Fludarabine Phosphate, Melphalan, and Alemtuzumab Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed Hodgkin Lymphoma
- Conditions
- Lymphoma
- First Posted Date
- 2009-05-22
- Last Posted Date
- 2013-08-02
- Lead Sponsor
- Cancer Research UK
- Target Recruit Count
- 49
- Registration Number
- NCT00907036